ArticlePloS one2024

Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.

Yao Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.